Latest News & Features
Africa
In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson. 12 October 2016
Americas
Mylan has agreed to pay the US Department of Justice and other government agencies $465 million to settle questions about the classification of EpiPen Auto-Injector under the Medicaid Drug Rebate Program. 11 October 2016
Americas
Pfizer has agreed to sell its infusion therapy business to US medical manufacturer ICU Medical for $1 billion. 11 October 2016
Asia
Over the past few years China’s life sciences sector has become a hive of activity as specialist IP courts have been implemented and M&A activity has ramped up. LSIPR assesses some of these developments. 11 October 2016
Big Pharma
In September 2016, the Francis Crick Institute opened the doors to its multimillion-pound new home in London. With a wide range of research being undertaken, LSIPR examines the role of IP and the associated challenges for the organisation. 11 October 2016
Americas
Ireland-based biopharmaceutical company Mallinckrodt and Endo, a US healthcare business, have won a patent case against Amneal and Teva. 10 October 2016
Africa
AstraZeneca and Cilag, an affiliate of Johnson & Johnson, have entered into an agreement for AstraZeneca to divest the rights to Rhinocort Aqua outside the US. 10 October 2016
Biotechnology
Dolly the Sheep, which would have been 20 this year, raised the possibility of cloning and forced politicians and IP practitioners to address the ethics of the process, with differing results in the US and the UK, as LSIPR reports. 10 October 2016
Africa
There is some debate about whether the ‘patent cliff’ or the need to innovate is driving M&A activity in the pharmaceutical industry, where billions of dollars have been spent in the past few years, as LSIPR finds out. 10 October 2016
Americas
Teva and South Korean biopharmaceutical company Celltrion have entered into an exclusive partnership to commercialise two of Celltrion’s biosimilars in the US and Canada. 7 October 2016